S&P 500   4,206.19 (+2.03%)
DOW   33,268.91 (+1.51%)
QQQ   325.37 (+2.61%)
AAPL   168.55 (+2.20%)
MSFT   288.16 (+2.08%)
META   177.60 (+5.38%)
GOOGL   119.44 (+2.41%)
AMZN   142.33 (+3.26%)
TSLA   877.69 (+3.26%)
NVDA   180.06 (+5.38%)
NIO   19.93 (+3.96%)
BABA   92.47 (+1.40%)
AMD   98.32 (+2.91%)
MU   61.26 (+3.57%)
T   18.04 (-0.33%)
CGC   3.31 (+15.33%)
GE   77.28 (+3.14%)
F   15.42 (+1.51%)
DIS   111.99 (+3.57%)
AMC   23.15 (+3.12%)
PYPL   97.93 (+3.65%)
PFE   49.74 (-0.08%)
NFLX   243.39 (+5.85%)
S&P 500   4,206.19 (+2.03%)
DOW   33,268.91 (+1.51%)
QQQ   325.37 (+2.61%)
AAPL   168.55 (+2.20%)
MSFT   288.16 (+2.08%)
META   177.60 (+5.38%)
GOOGL   119.44 (+2.41%)
AMZN   142.33 (+3.26%)
TSLA   877.69 (+3.26%)
NVDA   180.06 (+5.38%)
NIO   19.93 (+3.96%)
BABA   92.47 (+1.40%)
AMD   98.32 (+2.91%)
MU   61.26 (+3.57%)
T   18.04 (-0.33%)
CGC   3.31 (+15.33%)
GE   77.28 (+3.14%)
F   15.42 (+1.51%)
DIS   111.99 (+3.57%)
AMC   23.15 (+3.12%)
PYPL   97.93 (+3.65%)
PFE   49.74 (-0.08%)
NFLX   243.39 (+5.85%)
S&P 500   4,206.19 (+2.03%)
DOW   33,268.91 (+1.51%)
QQQ   325.37 (+2.61%)
AAPL   168.55 (+2.20%)
MSFT   288.16 (+2.08%)
META   177.60 (+5.38%)
GOOGL   119.44 (+2.41%)
AMZN   142.33 (+3.26%)
TSLA   877.69 (+3.26%)
NVDA   180.06 (+5.38%)
NIO   19.93 (+3.96%)
BABA   92.47 (+1.40%)
AMD   98.32 (+2.91%)
MU   61.26 (+3.57%)
T   18.04 (-0.33%)
CGC   3.31 (+15.33%)
GE   77.28 (+3.14%)
F   15.42 (+1.51%)
DIS   111.99 (+3.57%)
AMC   23.15 (+3.12%)
PYPL   97.93 (+3.65%)
PFE   49.74 (-0.08%)
NFLX   243.39 (+5.85%)
S&P 500   4,206.19 (+2.03%)
DOW   33,268.91 (+1.51%)
QQQ   325.37 (+2.61%)
AAPL   168.55 (+2.20%)
MSFT   288.16 (+2.08%)
META   177.60 (+5.38%)
GOOGL   119.44 (+2.41%)
AMZN   142.33 (+3.26%)
TSLA   877.69 (+3.26%)
NVDA   180.06 (+5.38%)
NIO   19.93 (+3.96%)
BABA   92.47 (+1.40%)
AMD   98.32 (+2.91%)
MU   61.26 (+3.57%)
T   18.04 (-0.33%)
CGC   3.31 (+15.33%)
GE   77.28 (+3.14%)
F   15.42 (+1.51%)
DIS   111.99 (+3.57%)
AMC   23.15 (+3.12%)
PYPL   97.93 (+3.65%)
PFE   49.74 (-0.08%)
NFLX   243.39 (+5.85%)
NASDAQ:CFMS

Conformis - CFMS Stock Forecast, Price & News

$0.30
+0.02 (+7.61%)
(As of 08/10/2022 03:08 PM ET)
Add
Compare
Today's Range
$0.28
$0.30
50-Day Range
$0.26
$0.42
52-Week Range
$0.25
$1.96
Volume
52,097 shs
Average Volume
746,172 shs
Market Capitalization
$54.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

Conformis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
596.6% Upside
$2.00 Price Target
Short Interest
Healthy
1.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of Conformis in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.31) to ($0.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

254th out of 1,108 stocks

Surgical Appliances & Supplies Industry

8th out of 22 stocks

CFMS stock logo

About Conformis (NASDAQ:CFMS) Stock

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.

Conformis Stock Performance

CFMS opened at $0.27 on Wednesday. The company has a fifty day moving average of $0.32 and a 200 day moving average of $0.49. The stock has a market capitalization of $50.94 million, a price-to-earnings ratio of -6.87 and a beta of 1.25. The company has a debt-to-equity ratio of 0.24, a quick ratio of 5.87 and a current ratio of 6.84. Conformis has a fifty-two week low of $0.25 and a fifty-two week high of $1.96.

Conformis (NASDAQ:CFMS - Get Rating) last posted its earnings results on Monday, August 8th. The medical instruments supplier reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). Conformis had a negative net margin of 6.83% and a negative return on equity of 6.50%. During the same quarter last year, the firm earned $0.21 earnings per share. As a group, sell-side analysts forecast that Conformis will post -0.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Conformis in a research note on Tuesday. They issued a "hold" rating for the company.

Receive CFMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conformis and its competitors with MarketBeat's FREE daily newsletter.

CFMS Stock News Headlines

Recap: Conformis Q2 Earnings - Benzinga
ConforMIS Q2 2022 Earnings Preview
Conformis (CFMS) to Release Earnings on Monday
StockNews.com Initiates Coverage on Conformis (NASDAQ:CFMS)
See More Headlines
Receive CFMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conformis and its competitors with MarketBeat's FREE daily newsletter.

CFMS Company Calendar

Last Earnings
8/08/2022
Today
8/10/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CFMS
Employees
310
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.00
High Stock Price Forecast
$2.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+576.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-2,410,000.00
Pretax Margin
-6.73%

Debt

Sales & Book Value

Annual Sales
$99.86 million
Book Value
$0.54 per share

Miscellaneous

Free Float
179,123,000
Market Cap
$54.81 million
Optionable
Not Optionable
Beta
1.25














CFMS Stock - Frequently Asked Questions

Should I buy or sell Conformis stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Conformis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CFMS shares.
View CFMS analyst ratings
or view top-rated stocks.

What is Conformis' stock price forecast for 2022?

1 analysts have issued 12 month target prices for Conformis' shares. Their CFMS share price forecasts range from $2.00 to $2.00. On average, they expect the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 576.4% from the stock's current price.
View analysts price targets for CFMS
or view top-rated stocks among Wall Street analysts.

How have CFMS shares performed in 2022?

Conformis' stock was trading at $0.7610 at the start of the year. Since then, CFMS stock has decreased by 61.1% and is now trading at $0.2957.
View the best growth stocks for 2022 here
.

Are investors shorting Conformis?

Conformis saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 1,700,000 shares, a decline of 30.3% from the July 15th total of 2,440,000 shares. Based on an average daily trading volume, of 851,600 shares, the short-interest ratio is currently 2.0 days. Currently, 1.0% of the company's shares are short sold.
View Conformis' Short Interest
.

When is Conformis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CFMS earnings forecast
.

How were Conformis' earnings last quarter?

Conformis, Inc. (NASDAQ:CFMS) announced its earnings results on Monday, August, 8th. The medical instruments supplier reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.01. Conformis had a negative trailing twelve-month return on equity of 6.50% and a negative net margin of 6.83%. During the same period last year, the company posted $0.21 earnings per share.

What is Mark Augusti's approval rating as Conformis' CEO?

15 employees have rated Conformis Chief Executive Officer Mark Augusti on Glassdoor.com. Mark Augusti has an approval rating of 55% among the company's employees. This puts Mark Augusti in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Conformis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Conformis investors own include Advanced Micro Devices (AMD), Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Trevena (TRVN), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and AT&T (T).

When did Conformis IPO?

(CFMS) raised $135 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is Conformis' stock symbol?

Conformis trades on the NASDAQ under the ticker symbol "CFMS."

Who are Conformis' major shareholders?

Conformis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (7.00%), Granite Point Capital Management L.P. (0.92%), Avidian Wealth Solutions LLC (0.47%) and Connor Clark & Lunn Investment Management Ltd. (0.31%). Insiders that own company stock include Erin Henry, J Brent Alldredge, Kenneth P Fallon III, Mark A Augusti, Mark A Augusti, Paul S Weiner and Robert S Howe.
View institutional ownership trends
.

How do I buy shares of Conformis?

Shares of CFMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Conformis' stock price today?

One share of CFMS stock can currently be purchased for approximately $0.30.

How much money does Conformis make?

Conformis (NASDAQ:CFMS) has a market capitalization of $54.83 million and generates $99.86 million in revenue each year. The medical instruments supplier earns $-2,410,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis.

How many employees does Conformis have?

The company employs 310 workers across the globe.

How can I contact Conformis?

Conformis' mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The official website for the company is www.conformis.com. The medical instruments supplier can be reached via phone at (781) 345-9001, via email at ir@conformis.com, or via fax at 781-345-0147.

This page (NASDAQ:CFMS) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.